Our meta-analysis included three RC

Our meta-analysis included three RCTs and two comparative control studies involving 184 patients. There were 89 patients in the rituximab arm and 95 patients in the control arm. Our results indicated that rituximab treatment could significantly improve the relapse-free survival rate in patients with NS compared with control therapy. Moreover, rituximab treatment seemed to achieve a higher complete remission rate (39.62% for rituximab versus 25.45% for the control). Furthermore, rituximab treatment significantly reduced the incidence of proteinuria. There were no significant differences in the serum albumin and serum creatinine levels or the estimated glomerular filtration rate between the two groups. The adverse effects were similar between the two arms, and no significance differences were observed.

Our study indicated that rituximab treatment demonstrated benefits in terms of relapse-free survival, which was consistent with previous studies. Gulati et al. reported that rituximab treatment in patients with SRNS or SDNS that was refractory to standard therapy could sustain long-term relapse-free survival30. A study from China reported that rituximab treatment demonstrated a 91.67% effective rate22. A recent review revealed that rituximab treatment reduced the number of relapses per year, with minimal change in disease and little focal segmental glomerulosclerosis31. Tellier et al. reported that 4 (22%) of 18 patients with idiopathic NS who were treated with rituximab experienced remission without relapse, and the remaining patients had increased durations of remission32. In patients who received one dose of rituximab (375 mg/m2), 25%–40% were in sustained remission at 12–17 months33, 34. Sinha A indicated that therapy with rituximab could reduce relapse rates in children with refractory NS

Hasil (Bahasa Indonesia) 1:

Our meta-analysis included three RCTs and two comparative control studies involving 184 patients. There were 89 patients in the rituximab arm and 95 patients in the control arm. Our results indicated that rituximab treatment could significantly improve the relapse-free survival rate in patients with NS compared with control therapy. Moreover, rituximab treatment seemed to achieve a higher complete remission rate (39.62% for rituximab versus 25.45% for the control). Furthermore, rituximab treatment significantly reduced the incidence of proteinuria. There were no significant differences in the serum albumin and serum creatinine levels or the estimated glomerular filtration rate between the two groups. The adverse effects were similar between the two arms, and no significance differences were observed.Penelitian kami menunjukkan bahwa pengobatan rituximab menunjukkan manfaat dalam hal kambuh kelangsungan hidup, yang konsisten dengan penelitian sebelumnya. Gulati et al. melaporkan bahwa rituximab treatment di pasien dengan SRNS atau SDNS yang refrakter terhadap terapi standar bisa mempertahankan jangka panjang bebas kambuh survival30. Sebuah studi dari Cina melaporkan bahwa pengobatan rituximab menunjukkan rate22 efektif 91.67%. Review baru-baru mengungkapkan bahwa pengobatan rituximab mengurangi jumlah kambuh per tahun, dengan sedikit perubahan dalam penyakit dan sedikit glomerulosclerosis31 segmental fokus. Tellier et al. melaporkan bahwa 4 (22%) dari 18 pasien dengan idiopathic NS yang diperlakukan dengan rituximab mengalami pengampunan tanpa kambuh, dan sisa pasien telah meningkat durasi dari remission32. Pada pasien yang menerima satu dosis rituximab (375 mg/m2), 25%-40% yang berkelanjutan pengampunan pada 12-17 months33, 34. Sinha A menunjukkan bahwa terapi dengan rituximab dapat mengurangi tingkat kekambuhan pada anak dengan bahan tahan api NS